Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding—transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

Abstract: The invention relates to direct-fed microbials for use in E. coli inhibition in animals. More particularly, the invention relates to isolated Bacillus strains 101, 235, 77, 177, and 102 and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention can also be used for treatment of plants and in food processing.

Abstract: Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.

Abstract: Compositions containing a combination of nicotinamide riboside and pterostilbene for treating neurodegenerative disorders, and methods of treating neurodegenerative disorders using these compositions and their equivalents are described. The neurodegenerative disorders that can be treated using these compositions or methods can include Parkinson's disease, Huntington's disease, Alzheimer's disease, and the like. In an embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene can be prepared as oral formulations. In some embodiments, a dietary supplement comprises nicotinamide riboside and/or pterostilbene or equivalents.

Abstract: Described is a fiber material having a substrate of non-ionic, non-woven fibers, and at least one additional component, which is an agent that comprises at least one group capable of forming a hydrogen bond, wherein the non-ionic, non-woven fibers are crosslinked by the agent. The fiber material can be of use in various fields, in particular household products, hygiene products and the like, these fiber materials are of particular use in wound treatment.

Abstract: A method and system to address the adverse effects on an individual's oral microbiome with the objective of restoring gingival health caused by exposure to sodium lauryl sulfate. Certain embodiments of the present invention facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries, halitosis, canker sores, and other oral diseases. Probiotic bacterial, bioactive flavonoid, xylitol and zinc compound compositions, provide effective prevention and treatment options, especially while precluding the use of sodium lauryl sulfate so as to reduce adverse consequences it has on gingival health.

Abstract: A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.

Abstract: The present disclosure relates generally to treatment and diagnosis of diseases, disorders or conditions characterized by vascular leakage. More particularly, the present disclosure relates to methods for treating a vascular leakage-associated disease or disorder in a subject; for reducing vascular leakage in a subject; for reducing reactive oxygen species production in a subject; for inducing apoptosis of neutrophils in a subject; and for increasing survival of a subject having a vascular leakage-associated disease or disorder. The methods comprise administering a G9a and/or G9a-like protein (GLP) methyltransferase inhibitor to the subject. The present disclosure further relates to methods for developing a treatment plan for a subject with a vascular leakage-associated disease, disorder or condition, and for identifying a subject as a candidate for treatment of a vascular leakage-associated disease or disorder.

Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

Abstract: Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.

Abstract: Immunogenic compositions that include SARS-CoV-2 spike (S) protein, S1 protein, or S2 protein, and an adjuvant, such as alum, or a combination of CpG oligodeoxynucleotide, Poly I:C, and IL-15, and nanoparticle compositions that include SARS-CoV-2 S protein, S1 protein, or S2 protein, and CpG oligonucleotide, poly(I:C), and IL-15, are provided. Also provided are methods of using such compositions, for example a prime intramuscular administration followed by one or more intranasal boosters that include the disclosed nanoparticles, to generate an immune response to SARS-CoV-2 in a subject, for example respiratory mucosal immunity, for example to prevent SARS-CoV-2 infection or transmission to other subjects.

Abstract: A ventilation assistance device and a method of using a ventilation assistance device for providing ventilation to a subject. The ventilation assistance device comprises a duct configured to be connectable between a source of gas and an interface device, for establishing fluid communication between the source of gas and the interface device for delivering gas to a subject's airway; a flow sensor configured to determine a flow volume of gas in the duct; and an operator interface configured to represent a measure of gas received by the subject by way of a plurality of indicators, each indicator being representative of the measure being within a particular range suitable for respective reference subjects having respective characteristics; wherein the operator interface is configured to display one of the plurality of indicators based on the flow volume determined by the flow sensor to represent to an operator the characteristic of the reference subject for which the gas received is suitable.

Abstract: The present invention relates to a cosmetic composition comprising carnitine-salicylate (CA-SA) as an active ingredient. In addition, the composition of the present invention, as a result of having CA-SA as the active ingredient, has been confirmed to alleviate acne and exfoliate dead skin cells as a skin improving substance while simultaneously alleviating inflammation and erythema as a skin soothing substance, due to ion pairing of carnitine and salicylate in mildly acidic conditions.

Abstract: The present invention relates to a cosmetic composition including a bee pollen exosome, more particularly, a cosmetic composition including the bee pollen exosome as an active ingredient, the cosmetic composition having excellent effects such as skin whitening, skin elasticity enhancement, wrinkle improvement, skin moisturizing, skin regeneration, skin soothing, skin radiance improvement or anti-inflammation, etc. Further, provided are a functional food composition and a quasi-drug composition, each including the bee pollen exosome.

Abstract: The present disclosure is directed to an SR-B1-targeting nanomicelle and compositions, methods of synthesis and methods of use thereof. The nanomicelle may be an HDL-mimetic drug delivery system and may be cross-linked with DSS. The composition may contain a therapeutic agent with the ability to treat cancers, especially sarcomas.

Abstract: A manipulator a heated massaging function includes a main body. Two first massage assemblies are symmetrically arranged on two sides of the main body. The main body is provided with a driving mechanism and is further provided with a second massage assembly in a middle position between the two first massage assemblies. The second massage assembly includes a base, a first extension arm, a second extension arm, and at least two rolling heating assemblies. One end of the first extension arm and one end of the second extension arm are connected to the base in a swinging manner, and an elastic member is provided at a swing connection. The other end of the first extension arm and the other end of the second extension arm extend towards the upper and lower sides of the manipulator, respectively.

Abstract: A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-?-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5?-azidopentyl)alanine, or L-/D-2-(6?-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-alanine.

Abstract: Systems and methods for monitoring of biometric and contextual variables to assist in screening for, quantification of, and prediction of smoking behavior, and for assisting in smoking cessation are described.